Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines

Carlisle,Samantha  M.; Hein,David  W.

doi:10.3892/ijo.2018.4436

Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines

Authors:
- Samantha M. Carlisle
- David W. Hein
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA
Published online on: June 11, 2018 https://doi.org/10.3892/ijo.2018.4436
Pages: 694-702
Copyright: © Carlisle et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression levels of estrogen receptor 1 (ESR1), arylamine N‑acetyltransferase 1 (NAT1), and arylamine N‑acetyltransferase 2 (NAT2) are implicated in breast cancer; however, their co-expression profiles in normal breast tissue, primary breast tumors and established breast cancer cell lines are undefined. NAT1 expression is widely reported to be associated with ESR1 expression and is frequently investigated in breast cancer etiology. Furthermore, the NAT2 phenotype has been reported to modify breast cancer risk in molecular epidemiological association studies. Understanding the relationships between the expression levels of these genes is essential to understand their role in breast cancer etiology and treatment. In the present study, NAT1, NAT2 and ESR1 expression data were accessed from repositories of RNA‑Seq data covering 57 breast cancer cell lines, 1,043 primary breast tumors and 99 normal breast tissues. The relationships between gene expression, and between NAT1 activity and RNA expression in breast cancer cell lines were evaluated using non-parametric statistical analyses. Differences in gene expression in each dataset, as well as gene expression differences in normal breast tissue compared to primary breast tumors, and stratification by estrogen receptor status were determined. NAT1 and NAT2 mRNA expression were detected in normal and primary breast tumor tissues; NAT1 expression was much higher than NAT2. NAT1 and ESR1 expression were strongly associated, whereas NAT2 and ESR1 expression were not. Although NAT1 and NAT2 expression were associated, the magnitude was moderate. NAT1, NAT2, and ESR1 expression were increased in primary breast tumor tissue compared with normal breast tissue; however, the magnitude and significance of the differences were lower for NAT2. Analysis of NAT1, NAT2, and ESR1 expression in normal and primary breast tissues and breast cancer cell lines suggested that NAT1 and NAT2 expression are regulated by distinctive mechanisms, whereas NAT1 and ESR1 expression may have overlapping regulation. Defining these relationships is important for future investigations into breast cancer prevention.

View Figures

View References

1	Hein DW: Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res. 506–507. 65–77. 2002.
2	Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA and Feng Y: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 9:29–42. 2000.
3	Bendaly J, Zhao S, Neale JR, Metry KJ, Doll MA, States JC, Pierce WM Jr and Hein DW: 2-Amino-3,8-dimethylimidazo-[4,5-f]quinoxaline-induced DNA adduct formation and mutagenesis in DNA repair-deficient Chinese hamster ovary cells expressing human cytochrome 4501A1 and rapid or slow acetylator N-acetyltransferase 2. Cancer Epidemiol Biomarkers Prev. 16:1503–1509. 2007. View Article : Google Scholar
4	Millner LM, Doll MA, Cai J, States JC and Hein DW: NATb/NAT1^4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1^4 following exposure to 4-aminobiphenyl. Mol Carcinog. 51:636–646. 2012. View Article : Google Scholar
5	Hein DW: Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 948:37–66. 1988.
6	Stepp MW, Mamaliga G, Doll MA, States JC and Hein DW: Folate-dependent hydrolysis of acetyl-Coenzyme A by recombinant human and rodent arylamine N-acetyltransferases. Biochem Biophys Rep. 3:45–50. 2015.
7	Laurieri N, Dairou J, Egleton JE, Stanley LA, Russell AJ, Dupret JM, Sim E and Rodrigues-Lima F: From arylamine N-acetyltransferase to folate-dependent acetyl CoA hydrolase: Impact of folic acid on the activity of (HUMAN)NAT1 and its homologue (MOUSE)NAT2. PLoS One. 9:e963702014. View Article : Google Scholar
8	Matas N, Thygesen P, Stacey M, Risch A and Sim E: Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet. 77:290–295. 1997. View Article : Google Scholar
9	Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah SJ, McCarthy A and Sim E: Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J. 297:441–445. 1994. View Article : Google Scholar
10	Grant DM, Blum M, Demierre A and Meyer UA: Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res. 17:39781989. View Article : Google Scholar
11	Kawamura A, Graham J, Mushtaq A, Tsiftsoglou SA, Vath GM, Hanna PE, Wagner CR and Sim E: Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 69:347–359. 2005. View Article : Google Scholar
12	Vatsis KP and Weber WW: Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys. 301:71–76. 1993. View Article : Google Scholar
13	Weber WW and Vatsis KP: Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 3:209–212. 1993. View Article : Google Scholar
14	Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL and Grewal R: Human acetyltransferase polymorphisms. Mutat Res. 376:61–70. 1997. View Article : Google Scholar
15	Cloete R, Akurugu WA, Werely CJ, van Helden PD and Christoffels A: Structural and functional effects of nucleotide variation on the human TB drug metabolizing enzyme arylamine N-acetyltransferase 1. J Mol Graph Model. 75:330–339. 2017. View Article : Google Scholar
16	McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB and Klein TE: PharmGKB summary: Very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 24:409–425. 2014.
17	Butcher NJ, Boukouvala S, Sim E and Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2:30–42. 2002. View Article : Google Scholar
18	Tiang JM, Butcher NJ and Minchin RF: Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med. 4:565–574. 2015. View Article : Google Scholar
19	Tiang JM, Butcher NJ, Cullinane C, Humbert PO and Minchin RF: RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One. 6:e170312011. View Article : Google Scholar
20	Tiang JM, Butcher NJ and Minchin RF: Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 393:95–100. 2010. View Article : Google Scholar
21	Stepp MW, Doll MA, Carlisle SM, States JC and Hein DW: Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231. Mol Carcinog. 57:549–558. 2018. View Article : Google Scholar
22	Stepp MW, Doll MA, Samuelson DJ, Sanders MA, States JC and Hein DW: Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism. BMC Cancer. 17:2332017. View Article : Google Scholar
23	Carlisle SM, Trainor PJ, Yin X, Doll MA, Stepp MW, States JC, Zhang X and Hein DW: Untargeted polar metabolomics of transformed MDA-MB-231 breast cancer cells expressing varying levels of human arylamine N-acetyltransferase 1. Metabolomics. 12:1112016. View Article : Google Scholar
24	Witham KL, Minchin RF and Butcher NJ: Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway. Biochem Pharmacol. 125:93–100. 2017. View Article : Google Scholar
25	Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX and Lee JC: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 96:9212–9217. 1999. View Article : Google Scholar
26	Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D and Børresen-Dale AL: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 15:2523–2536. 2004. View Article : Google Scholar
27	Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME and Yu J: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 365:671–679. 2005. View Article : Google Scholar
28	Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, Hurst HC and Sim E: Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer. 47:118–126. 2008. View Article : Google Scholar
29	Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R and Bieche I: Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer. 13:1109–1120. 2006. View Article : Google Scholar
30	Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, Sahin A and Aldaz CM: Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics. 6:372005. View Article : Google Scholar
31	Bièche I, Girault I, Urbain E, Tozlu S and Lidereau R: Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 6:R252–R263. 2004. View Article : Google Scholar
32	Zhang X, Carlisle SM, Doll MA, Martin RCG, States JC, Klinge CM and Hein DW: High N-acetyltransferase 1 expression is associated with estrogen receptor expression in breast tumors, but is not under direct regulation by estradiol, 5α-androstane-3β,17β-diol, or dihydrotestosterone in breast cancer cells. J Pharmacol Exp Ther. 365:84–93. 2018. View Article : Google Scholar
33	Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG and Chang-Claude J: Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: Pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 17:15–26. 2008. View Article : Google Scholar
34	Sadrieh N, Davis CD and Snyderwine EG: N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res. 56:2683–2687. 1996.
35	Husain A, Zhang X, Doll MA, States JC, Barker DF and Hein DW: Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos. 35:721–727. 2007. View Article : Google Scholar
36	Lee JH, Chung JG, Lai JM, Levy GN and Weber WW: Kinetics of arylamine N-acetyltransferase in tissues from human breast cancer. Cancer Lett. 111:39–50. 1997. View Article : Google Scholar
37	Husain A, Barker DF, States JC, Doll MA and Hein DW: Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics. 14:397–406. 2004. View Article : Google Scholar
38	Geylan YS, Dizbay S and Güray T: Arylamine N-acetyltransferase activities in human breast cancer tissues. Neoplasma. 48:108–111. 2001.
39	Geylan-Su YS, Isgör B, Coban T, Kapucuoglu N, Aydintug S, Iscan M, Iscan M and Güray T: Comparison of NAT1, NAT2 and GSTT2-2 activities in normal and neoplastic human breast tissues. Neoplasma. 53:73–78. 2006.
40	Deitz AC: N-acetyltransferase genetic polymorphisms and breast cancer risk. In: PhD dissertation. University of North Dakota; 1999
41	Jefferson FA, Xiao GH and Hein DW: 4-Aminobiphenyl downregulation of NAT2 acetylator genotype-dependent N- and O-acetylation of aromatic and heterocyclic amine carcinogens in primary mammary epithelial cell cultures from rapid and slow acetylator rats. Toxicol Sci. 107:293–297. 2009. View Article : Google Scholar
42	Bradshaw TD, Chua MS, Orr S, Matthews CS and Stevens MF: Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445). Br J Cancer. 83:270–277. 2000. View Article : Google Scholar
43	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV and Sonkin D: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar
44	Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM; Cancer Genome Atlas Research Network: The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 45:1113–1120. 2013. View Article : Google Scholar
45	Deng M, Bragelmann J, Kryukov I, Saraiva-Agostinho N and Perner S: FirebrowseR: an R client to the Broad Institute’s Firehose Pipeline. Database (Oxford) 2017. baw1602017. View Article : Google Scholar
46	Dai X, Cheng H, Bai Z and Li J: Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 8:3131–3141. 2017. View Article : Google Scholar
47	American Type Culture Collection (ATCC©): Breast cancer and normal cell lines. 2013, https://www.atcc.org/~/media/PDFs/Cancer%20and%20Normal%20cell%20lines%20tables/Breast%20cancer%20and%20normal%20cell%20lines.ashx. Accessed Feb 2, 2018.
48	Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 4:e61462009. View Article : Google Scholar
49	R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2017, http://www.R-project.org/. Accessed Dec 15, 2017.
50	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA and Reddel RR: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar
51	Thorpe SM: Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance Acta Oncol. 27:1–19. 1988.
52	Williams JA, Stone EM, Fakis G, Johnson N, Cordell JA, Meinl W, Glatt H, Sim E and Phillips DH: N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics. 11:373–388. 2001. View Article : Google Scholar
53	AbuHammad S and Zihlif M: Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics. 101:213–220. 2013. View Article : Google Scholar
54	Hein DW: N-acetyltransferase 2 polymorphism and human urinary bladder and breast cancer risks. Arylamine N-Acetyltransferases in Health and Disease: From Pharmacogenetics to Drug Discovery and Diagnostics. Laurieri N and Sim E: World Scientific Publishing; Singapore: pp. 327–349. 2018, View Article : Google Scholar
55	Butcher NJ and Minchin RF: Arylamine N-acetyltransferase 1: A novel drug target in cancer development. Pharmacol Rev. 64:147–165. 2012. View Article : Google Scholar
56	Laurieri N, Egleton JE and Russell AJ: Human N-acetyltransferase type 1 and breast cancer. Arylamine N-Acetyltransferases in Health and Disease: From Pharmacogenetics to Drug Discovery and Diagnostics. Laurieri N and Sim E: World Scientific Publishing; Singapore: pp. 351–384. 2018, View Article : Google Scholar